In line with the clinical results, our established GBC organoids were largely heterogeneous and highly resistant to multiple targeted drugs approved by the FDA for tumour therapy, such as JAK‐STAT, protein kinase B, PKB (PI3K‐AKT) and PARP inhibitors. The gene discussed is AKT1; the disease is neoplasm.